JOHN W. HUEMOELLER II - 15 Mar 2024 Form 4/A Insider Report for AXIM BIOTECHNOLOGIES, INC. (AXIM)

Role
Chief Executive Officer, Director
Signature
/s/ John W. Huemoeller II
Issuer symbol
AXIM
Transactions as of
15 Mar 2024
Net transactions value
+$125,000,000,000
Form type
4/A
Filing time
19 Mar 2024, 19:59:06 UTC
Date Of Original Report
19 Mar 2024
Previous filing
23 Sep 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AXIM Convertible Note Award $62,500,000,000 +250,000 +0.84% $250000.00* 30,000,000 15 Mar 2024 Common Stock 25,000,000 $0.0100 Direct F1
transaction AXIM Convertible Note Award $62,500,000,000 +250,000 +0.59% $250000.00* 42,500,000 15 Mar 2024 Common Stock 12,500,000 $0.0200 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reporting Person acquired an Amended Convertible Promissory Note in the face amount of $250,000. The Note is convertible into shares of the Issuer's common stock at a price of $0.01 per share.
F2 Reporting Person acquired a convertible note, face value $250,000. The note is convertible into shares of Issuer's common stock at a price of $0.02 per share.